Cargando…
The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer
Drug resistance remains a barrier in the clinical treatment of ovarian cancer. Proteasomal and antioxidant activities play important roles in tumor drug resistance, and increasing evidence suggests the existence of an interaction between antioxidant and proteasomal activities. However, the mechanism...
Autores principales: | Deng, Xinyue, Lin, Nan, Fu, Jiaying, Xu, Long, Luo, Haoge, Jin, Yao, Liu, Yanan, Sun, Liankun, Su, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714579/ https://www.ncbi.nlm.nih.gov/pubmed/33294122 http://dx.doi.org/10.1155/2020/4830418 |
Ejemplares similares
-
PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway
por: Li, Yanqing, et al.
Publicado: (2021) -
p53 Affects PGC1α Stability Through AKT/GSK-3β to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer
por: Deng, Xinyue, et al.
Publicado: (2020) -
ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells
por: Xu, Yunjie, et al.
Publicado: (2018) -
p53/PGC-1α-mediated mitochondrial dysfunction promotes PC3 prostate cancer cell apoptosis
por: Li, Jiuling, et al.
Publicado: (2020) -
Diallyl trisulfide alleviates chemotherapy sensitivity of ovarian cancer via the AMPK/SIRT1/PGC1α pathway
por: Wang, Zhaojun, et al.
Publicado: (2022)